{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T10:48:42Z","timestamp":1758970122953},"reference-count":19,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.schres.2012.01.043","type":"journal-article","created":{"date-parts":[[2012,2,23]],"date-time":"2012-02-23T17:02:31Z","timestamp":1330016551000},"page":"137-140","source":"Crossref","is-referenced-by-count":5,"title":["Impact of the CATIE trial on antipsychotic prescribing patterns at a state psychiatric facility"],"prefix":"10.1016","volume":"137","author":[{"given":"Angela M.","family":"Koranek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tawny L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa M.","family":"Mican","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen L.","family":"Rascati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2012.01.043_bb0100","article-title":"The impact of the clinical antipsychotic trials of intervention effectiveness (CATIE) on prescribing practices: an analysis of data from a large midwestern state","author":"Berkowitz","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2012.01.043_bb0010","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archpsyc.60.6.553","article-title":"A meta-analysis of the efficacy of second-generation antipsychotics","volume":"60","author":"Davis","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2012.01.043_bb0105","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","article-title":"Randomized controlled trial of the effect on quality of life of second vs. first generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1)","volume":"63","author":"Jones","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2012.01.043_bb0020","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1176\/appi.ajp.2009.08121809","article-title":"Clinical trials design lessons from the CATIE study","volume":"166","author":"Kraemer","year":"2009","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2012.01.043_bb0025","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/oxfordjournals.schbul.a006996","article-title":"Racial disparity in the pharmacological management of schizophrenia","volume":"29","author":"Kreyenbuhl","year":"2003","journal-title":"Schizophr. Bull."},{"issue":"4","key":"10.1016\/j.schres.2012.01.043_bb0030","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJM199207233270405","article-title":"Do the results of randomized clinical trials of cardiovascular drugs influence medical practice?","volume":"327","author":"Lamas","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.schres.2012.01.043_bb0035","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2012.01.043_bb0040","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/S0140-6736(03)13306-5","article-title":"New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis","volume":"361","author":"Leucht","year":"2003","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.schres.2012.01.043_bb0045","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.schres.2012.01.043_bb0050","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2710.2009.01047.x","article-title":"Impact of ALLHAT publication on antihypertensive prescribing patterns in Regione Emilia-Romagna, Italy","volume":"35","author":"Maio","year":"2010","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.schres.2012.01.043_bb0055","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1345\/aph.1A109","article-title":"Interrupted time series in clinical research","volume":"37","author":"Matowe","year":"2003","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.schres.2012.01.043_bb0060","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.mp.4001556","article-title":"Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs","volume":"10","author":"Miyamoto","year":"2005","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2012.01.043_bb0065","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1176\/ajp.2006.163.12.2080","article-title":"Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia","volume":"163","author":"Rosenheck","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"20","key":"10.1016\/j.schres.2012.01.043_bb0070","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1001\/jama.290.20.2693","article-title":"Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. A randomized controlled trial","volume":"290","author":"Rosenheck","year":"2003","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.schres.2012.01.043_bb0075","doi-asserted-by":"crossref","first-page":"317","DOI":"10.18553\/jmcp.2010.16.5.317","article-title":"Cost and utilization of behavioral health medications associated with rescission of an exemption for prior authorization for severe and persistent mental illness in the Vermont Medicaid program","volume":"16","author":"Simeone","year":"2010","journal-title":"J. Manage. Care Pharm."},{"issue":"12","key":"10.1016\/j.schres.2012.01.043_bb0080","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1377\/hlthaff.2010.1296","article-title":"Medicaid cost control measures aimed at second-generation antipsychotics led to less use of all antipsychotics","volume":"30","author":"Vogt","year":"2011","journal-title":"Heal. Aff."},{"key":"10.1016\/j.schres.2012.01.043_bb0085","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0920-9964(99)00154-1","article-title":"Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life","volume":"43","author":"Voruganti","year":"2000","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2012.01.043_bb0090","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1365-2710.2002.00430.x","article-title":"Segmented regression analysis of interrupted time series studies in medication use research","volume":"27","author":"Wagner","year":"2002","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.schres.2012.01.043_bb0095","doi-asserted-by":"crossref","first-page":"663","DOI":"10.4088\/JCP.v64n0607","article-title":"Chlorpromazine equivalent doses for the newer atypical antipsychotics","volume":"64","author":"Woods","year":"2003","journal-title":"J. Clin. Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996412000680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996412000680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T17:18:07Z","timestamp":1640884687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996412000680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":19,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0920996412000680"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2012.01.043","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}